Skip to main content
. 2010 Nov 10;2010(11):CD005197. doi: 10.1002/14651858.CD005197.pub3

Oppenheim 2000.

Methods RCT
 Open
Participants Number: 80 episodes
 Age: mean 45.6
Interventions piperacillin‐tazobactam 4.5grX3
 versus
 meropenem 1grX3
Outcomes Overall and infection‐related mortality ‐ at end of treatment
 Clinical and microbiological failure
Notes UK
 Study terminated early because of problems with supply of one of the study drugs and therefore unpublished.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence generation? Unclear risk No description
Allocation concealment? Unclear risk No description
Blinding? 
 All outcomes High risk Blinding not used
Incomplete outcome data addressed? 
 All‐cause mortality High risk 2% dropouts
Incomplete outcome data addressed? 
 Treatment failure High risk Number of dropouts (2%) known per study group
Free of other bias? High risk Unit of randomization = episodes; number of patients unknown